about
Allopurinol for preventing mortality and morbidity in newborn infants with hypoxic-ischaemic encephalopathyFebuxostat for treating chronic goutFebuxostat for treating chronic goutAllopurinol for preventing mortality and morbidity in newborn infants with suspected hypoxic-ischaemic encephalopathyHLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemiaTherapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinolRasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in goutTreatment of hyperuricemia in gout: current therapeutic options, latest developments and clinical implicationsAssociation of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysisMechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and goutEfficacy and Safety of Chinese Medicinal Herbs for the Treatment of Hyperuricemia: A Systematic Review and Meta-AnalysisAllopurinol: insights from studies of dose-response relationships.Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements.Efficacy and safety of desensitization to allopurinol following cutaneous reactions.Tumor lysis syndrome: new challenges and recent advances.Allopurinol hypersensitivity syndrome revisited.Management of hyperuricemia in gout: focus on febuxostat.Uric acid: a novel mediator and marker of risk in chronic kidney disease?Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndromeNew steroidal saponin from Antigonon leptopus Hook. and Arn.An old disease with new insights: Update on diagnosis and treatment of gout.Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.Fatal allopurinol hypersensitivity syndrome after treatment of asymptomatic hyperuricaemia.Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without goutThe management of hyperuricemia and gout in patients with heart failure.A case series of allopurinol-induced toxic epidermal necrolysisAdvances in the management of gout: critical appraisal of febuxostat in the control of hyperuricemia.Potential pharmacologic treatments for cystinuria and for calcium stones associated with hyperuricosuria.Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeuticsAllopurinol reduces antigen-specific and polyclonal activation of human T cells.An update on the treatment options for gout and calcium pyrophosphate deposition.Severe cutaneous reactions requiring hospitalization in allopurinol initiators: a population-based cohort study.Hydroxylated chalcones with dual properties: Xanthine oxidase inhibitors and radical scavengers.Allopurinol, erythema multiforme, and renal insufficiency.Predicting allopurinol response in patients with goutDrug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome induced by celecoxib and anti-tuberculosis drugs.Development of Therapeutic Chimeric Uricase by Exon Replacement/Restoration and Site-Directed MutagenesisA comparative study of efficacy and safety of febuxostat and allopurinol in pyrazinamide-induced hyperuricemic tubercular patients.Understanding the dose-response relationship of allopurinol: predicting the optimal dosage.
P2860
Q24202191-FCB1F1AB-698C-40F1-B761-AEDA0D91DAD3Q24202984-F4EFBA7E-4CBB-425F-976F-004CD4E57599Q24236637-61B5E151-8B8A-4647-9B7B-7959D97DBDD9Q24242942-5E8ECA1D-B763-44A5-99B2-7684882896C9Q24555784-B32AF941-5F52-4CB5-8444-332513CCB66DQ24612292-5E76EEEC-31D6-4876-A673-79020982BB66Q24652967-EF2D738E-4229-48BF-83B4-D3341C3483BEQ24673444-1A2EF907-BEC7-415F-AECA-1FC62FD958AAQ26738948-25565BFE-B647-4B22-B881-CC8AA20B239EQ26853305-FAD53FF1-2932-4021-9FCA-019D039988F7Q27023909-16C84051-7F06-440D-A141-CEEA362F172CQ28071762-72244064-127A-4336-9185-E89162EDD57FQ30240163-FC2C9563-7156-4B20-A57B-F42D2F4EF488Q30565638-E457A0A7-F902-4CDD-9BDE-0CEC40055229Q32045067-F3C808D8-6033-4C17-B27D-C2A437BB16B5Q33595615-4086F2EC-23F3-4FB8-8B1D-E3A2EA3B2937Q33608523-053FFA09-D65E-4766-BCB7-42A5194B243BQ33635542-6414D0D8-5B9B-415A-BFEF-E26D18C17C23Q33913892-3A832076-E60F-458A-B3ED-AEF6164E91F1Q34141630-8C48E0A5-5FE3-4202-A1A5-2E5779240FE8Q34304504-05A9A85B-D6A5-4C52-B49C-7E42FEFC633BQ34542091-55503D0F-36DF-46DC-9E01-7032852164DDQ34572852-35FB07DB-EBC7-42DC-95B6-FAF7BB078F46Q34651002-29501609-626D-4503-B122-6F41753C5D3AQ34737229-52B646D5-9DE4-4593-BFF4-A11177CC562EQ34776806-D35E3E92-F83A-462E-B652-35AB109D21D1Q34941868-4A4EB51D-12CE-4282-8C84-B169EDCDD38DQ35026721-BC1D6942-00AA-4231-B23E-68B37D4586A4Q35165543-A4835F9C-F70B-4D72-9B75-4E4DA5739493Q35578918-8A7FE44F-CC3D-45CA-860E-008CB6E04074Q36250232-CAB7B404-EBCB-4026-B50B-6F2744E74EE8Q36301585-83F2C676-DF56-45F8-8016-086CCB39C8FAQ36413071-8F79586B-84D7-47A0-A409-39A558A6D233Q36535526-292C32A2-162A-4FBE-B2F4-B06D1CA342FFQ36596307-45FFCCDE-0BB4-4CCB-B417-CA57FA3FD22FQ36802064-BE7CFF0F-A62D-4904-BB03-6E958821ED79Q36854641-BBB00D2D-25A0-43E4-957C-A79009E1FC46Q36939339-D6073B83-AA1F-47A7-B6C0-8B334C598F0AQ37311966-CBAA1582-ADE2-4938-984F-00CACBBD103BQ37353448-FB2D8D59-E09B-44D8-837D-A9CCADE1C8F8
P2860
description
1993 nî lūn-bûn
@nan
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
1993年论文
@zh
1993年论文
@zh-cn
name
Allopurinol hypersensitivity syndrome: a review.
@en
type
label
Allopurinol hypersensitivity syndrome: a review.
@en
prefLabel
Allopurinol hypersensitivity syndrome: a review.
@en
P2860
P1476
Allopurinol hypersensitivity syndrome: a review.
@en
P2093
F Arellano
J A Sacristán
P2860
P304
P356
10.1177/106002809302700317
P407
P577
1993-03-01T00:00:00Z